专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2008100106A1 CONTROLLED RELEASE PREPARATION CONTAINING CILOSTAZOLAND PROCESS FOR THE PREPARATION THEREOF 审中-公开
标题翻译：含有CILOSTAZOLAND过程的控制释放制剂的制备
公开(公告)号：WO2008100106A1
公开(公告)日：2008-08-21
申请号：PCT/KR2008/000901
申请日：2008-02-15
申请人： AMOREPACIFIC CORPORATION , PACIFIC PHARMACEUTICAL CO., LTD. , PARK, Jin Woo , SHIN, Kwang Hyun , KWON, Min Jung , BAE, Joon Ho , JEON, Do Yong
发明人： PARK, Jin Woo , SHIN, Kwang Hyun , KWON, Min Jung , BAE, Joon Ho , JEON, Do Yong
IPC分类号： A61K9/10
CPC分类号： A61K9/2054 , A61K9/1635 , A61K9/1652 , A61K9/1694 , A61K9/205 , A61K9/2077 , A61K31/4709
摘要： A controlled release preparation which comprises particles containing cilostazol or its pharmaceutically acceptable salt dispersed in a solubilizing agent and an erodible material encasing said particles which is capable of forming a hydrogel, can maintain a constant level of cilostazol in the blood through its slow release during its prolonged residence time in the stomach and intestines, thereby minimizing adverse effects caused by rapid release of the drug or solubilizing agent.
摘要翻译：包含分散在增溶剂中的含有西洛他唑或其药学上可接受的盐的颗粒的控制释放制剂和包含能形成水凝胶的所述颗粒的可侵蚀材料可以通过其中缓慢释放来维持血液中恒定水平的西洛他唑在胃和肠中延长停留时间，从而最小化药物或增溶剂快速释放引起的不良反应。

2. 发明申请

WO2008100107A1 CONTROLLED-RELEASE PREPARATION CONTAINING CILOSTAZOL AND PROCESS FOR THE PREPARATION THEREOF 审中-公开
标题翻译：含有西兰坦的控制释放制剂及其制备方法
公开(公告)号：WO2008100107A1
公开(公告)日：2008-08-21
申请号：PCT/KR2008/000902
申请日：2008-02-15
申请人： AMOREPACIFIC CORPORATION , PACIFIC PHARMACEUTICAL CO., LTD. , PARK, Jin Woo , SHIN, Kwang Hyun , BIN, Sung Ah , LEE, Hyeok , BAE, Joon Ho , JEON, Do Yong
发明人： PARK, Jin Woo , SHIN, Kwang Hyun , BIN, Sung Ah , LEE, Hyeok , BAE, Joon Ho , JEON, Do Yong
IPC分类号： A61K9/22 , A61K9/20 , A61K47/34 , A61K9/36 , A61K31/47
CPC分类号： A61K9/0065 , A61K9/2031 , A61K9/2054 , A61K31/4709
摘要： The present invention relates to a controlled-release formulation comprising cilostazol and a method for preparing said formultion. The inventive controlled-release formulation comprising cilostazol or a pharmaceutically acceptable salt thereof, a solubilizing agent, a swelling agent, a swell-controlling agent and a gas generating material has advantages in that it maintains a constant cilostazol level in the blood through a slow release while it resides in the stomach and intestines over a long period of time, thereby increasing the absorption of cilostazol in the small intestine, the major absorption site of cilostazol, as well as minimizing adverse effects caused by rapid release and making it easy for a patient to take the drug.
摘要翻译：本发明涉及包含西洛他唑的控释制剂及其制备方法。包含西洛他唑或其药学上可接受的盐，增溶剂，溶胀剂，溶胀控制剂和气体发生材料的本发明的控制释放制剂具有以下优点：其通过缓慢释放维持血液中恒定的西洛他唑水平而长时间存在于胃和肠中，从而增加西洛他唑的主要吸收部位小肠西洛他唑的吸收，同时减少由快速释放引起的不良反应，使病人容易服用药物

3. 发明专利

JP2010519201A Controlled release formulation and a method of manufacturing the same, including the cilostazol 审中-公开
公开(公告)号：JP2010519201A
公开(公告)日：2010-06-03
申请号：JP2009549533
申请日：2008-02-15
申请人：アモーレパシフィックコーポレイションAmorepacific Corporation , パシフィックファーマシューティカルカンパニーリミテッドPacific Pharmaceutical Co., Ltd.
发明人：ジョン・ドヨン , シン・クワンヒュン , パク・ジンウォ , ビン・スンア , ペ・ジョンホ , リ・ヒョク
IPC分类号： A61K31/4709 , A61K9/22 , A61K9/26 , A61K9/28 , A61K9/48 , A61K47/02 , A61K47/04 , A61K47/08 , A61K47/10 , A61K47/12 , A61K47/14 , A61K47/18 , A61K47/20 , A61K47/22 , A61K47/24 , A61K47/26 , A61K47/32 , A61K47/34 , A61K47/36 , A61K47/38 , A61K47/40 , A61K47/44 , A61P7/02 , A61P9/08 , A61P9/10 , A61P11/06 , A61P29/00 , A61P43/00 , C07D401/12
CPC分类号： A61K9/0065 , A61K9/2031 , A61K9/2054 , A61K31/4709
摘要： The present invention relates to a controlled-release formulation comprising cilostazol and a method for preparing said formulation. The inventive controlled-release formulation comprising cilostazol or a pharmaceutically acceptable salt thereof, a solubilizing agent, a swelling agent, a swell-controlling agent and a gas generating material has advantages in that it maintains a constant cilostazol level in the blood through a slow release while it resides in the stomach and intestines over a long period of time, thereby increasing the absorption of cilostazol in the small intestine, the major absorption site of cilostazol, as well as minimizing adverse effects caused by rapid release and making it easy for a patient to take the drug.

4. 发明专利

JP2010519200A Controlled release formulation and a method of manufacturing the same, including the cilostazol 审中-公开
公开(公告)号：JP2010519200A
公开(公告)日：2010-06-03
申请号：JP2009549532
申请日：2008-02-15
申请人：アモーレパシフィックコーポレイションAmorepacific Corporation , パシフィックファーマシューティカルカンパニーリミテッドPacific Pharmaceutical Co., Ltd.
发明人：クウォン・ミンジュン , ジョン・ドヨン , シン・クワンヒュン , パク・ジンウォ , ペ・ジョンホ
IPC分类号： A61K31/4709 , A61K9/20 , A61K47/12 , A61K47/20 , A61K47/26 , A61K47/32 , A61K47/38 , A61P7/02
CPC分类号： A61K9/2054 , A61K9/1635 , A61K9/1652 , A61K9/1694 , A61K9/205 , A61K9/2077 , A61K31/4709
摘要： A controlled release preparation which comprises particles containing cilostazol or its pharmaceutically acceptable salt dispersed in a solubilizing agent and an erodible material encasing said particles which is capable of forming a hydrogel, can maintain a constant level of cilostazol in the blood through its slow release during its prolonged residence time in the stomach and intestines, thereby minimizing adverse effects caused by rapid release of the drug or solubilizing agent.

5. 发明专利

JP2004508034A Tsutsugamushi disease diagnosis for gene recombinant protein 审中-公开
公开(公告)号：JP2004508034A
公开(公告)日：2004-03-18
申请号：JP2002525230
申请日：2001-09-07
申请人：キムイクサンKIM, Ik Sang , セオセウヨンSEONG, Seung Yong , パシフィックファーマスーティカルカンパニーリミテッドPacific Pharmaceutical Co. Ltd.
发明人：キム　イク　サン , セオ　セウ　ヨン
IPC分类号： C12N15/09 , C07K14/29 , C07K14/44 , C07K14/705 , C07K19/00 , C12N1/15 , C12N1/19 , C12N1/21 , C12N5/10 , C12P21/02
CPC分类号： C07K14/29 , C07K2319/00
摘要：本発明は、ツツガムシ病診断用遺伝子組み換え抗原蛋白質に関するもので、オリエンティアツツガムシの抗原決定基から由来した２種以上の蛋白の遺伝子を連結したＤＮＡを含むベクトルで形質転換させた菌株を培養して得られる遺伝子組み換え蛋白質抗原を用いて、ツツガムシ病を診断する方法によれば、オリエンティアツツガムシ病源体を培養して診断用抗原として使用する間接免疫蛍光抗体法に相応する診断感応度及び特異性も有するので、これを利用する場合、ツツガムシ病診断の既存剤型が有している限界の病源体培養を必要としないだけでなく、単一遺伝子組み換え蛋白を使用する場合と比べて診断感応度が増加し、別途に生産された単一遺伝子組み換え蛋白を混合して使用することに比べて、生産費用を減少させることができる、優秀な診断用剤型を経済的に確保することができる。

6. 发明公开

EP2120887A1 CONTROLLED-RELEASE PREPARATION CONTAINING CILOSTAZOL AND PROCESS FOR THE PREPARATION THEREOF 审中-公开
标题翻译：根据上述制造控释和方法含西洛他唑备
公开(公告)号：EP2120887A1
公开(公告)日：2009-11-25
申请号：EP08712524.1
申请日：2008-02-15
申请人： Amorepacific Corporation , Pacific Pharmaceutical Co., Ltd.
发明人： PARK, Jin Woo , SHIN, Kwang Hyun , BIN, Sung Ah , LEE, Hyeok , BAE, Joon Ho , JEON, Do Yong
IPC分类号： A61K9/22 , A61K9/20 , A61K47/34 , A61K9/36 , A61K31/47
CPC分类号： A61K9/0065 , A61K9/2031 , A61K9/2054 , A61K31/4709
摘要： The present invention relates to a controlled-release formulation comprising cilostazol and a method for preparing said formultion. The inventive controlled-release formulation comprising cilostazol or a pharmaceutically acceptable salt thereof, a solubilizing agent, a swelling agent, a swell-controlling agent and a gas generating material has advantages in that it maintains a constant cilostazol level in the blood through a slow release while it resides in the stomach and intestines over a long period of time, thereby increasing the absorption of cilostazol in the small intestine, the major absorption site of cilostazol, as well as minimizing adverse effects caused by rapid release and making it easy for a patient to take the drug.

7. 发明公开

EP0746311A1 MEDICINAL PATCHES FOR PERCUTANEOUS ADMINISTRATION 失效
标题翻译：药物补丁经皮给药
公开(公告)号：EP0746311A1
公开(公告)日：1996-12-11
申请号：EP95941909.0
申请日：1995-12-23
申请人： PACIFIC CORPORATION , PACIFIC PHARMACEUTICAL CO. LTD.
发明人： KIM, Jung Ju , BAE, Woo Hyun , LEE, Yoo Chul , CHOI, Yang Gyu, Pacific R & D Center Dormitory
IPC分类号： A61K9
CPC分类号： A61K9/7053 , A61K9/7061 , A61K9/7092
摘要： Disclosed herein is a transdermal skin patch to adhere to a patient's skin, which comprises a water-impermeable backing layer; a liner; and between the two, a multilayer laminated of from 2 to 5 adhesive layers, each of said adhesive layers comprising an active ingredient, an adhesive resin, and a penetration enhancer, wherein each adhesive layer contains no water and has a different water absorption capacity in which the lowest layer which is to be contacted with the skin has the lowest water absorption capacity and the most upper layer in contact with the backing layer has the highest water absorption capacity, and said penetration enhancer being hexylene glycol present in an amount of 0.5 to 40 % by weight. The patch of the present invention contains hexylene glycol as a penetration enhancer, which allows an efficient enhancement of the penetration of active ingredient through the skin, as well as can be applied to the skin safely.
摘要翻译：本文公开了粘附于患者皮肤的透皮皮肤贴剂，其包含不透水的背衬层; 衬里; 以及在两者之间，由2至5个粘合剂层的多层层压制品，每个所述粘合剂层包含活性成分，粘合剂树脂和渗透促进剂，其中每个粘合剂层不含水并且具有不同的吸水能力其中与皮肤接触的最低层具有最低的吸水能力，并且与背衬层接触的最上层具有最高的吸水能力，并且所述渗透促进剂是己二醇的存在量为0.5至 40重量％。本发明的贴剂含有己二醇作为渗透促进剂，其允许有效增强活性成分穿过皮肤的渗透，并且可以安全地施用于皮肤。

8. 发明公开

EP2124891A1 CONTROLLED RELEASE PREPARATION CONTAINING CILOSTAZOLAND PROCESS FOR THE PREPARATION THEREOF 审中-公开
标题翻译：含有CILOSTAZOLAND工艺的控制释放制剂及其制备方法
公开(公告)号：EP2124891A1
公开(公告)日：2009-12-02
申请号：EP08712523.3
申请日：2008-02-15
申请人： Amorepacific Corporation , Pacific Pharmaceutical Co., Ltd.
发明人： PARK, Jin Woo , SHIN, Kwang Hyun , KWON, Min Jung , BAE, Joon Ho , JEON, Do Yong
IPC分类号： A61K9/10
CPC分类号： A61K9/2054 , A61K9/1635 , A61K9/1652 , A61K9/1694 , A61K9/205 , A61K9/2077 , A61K31/4709
摘要： A controlled release preparation which comprises particles containing cilostazol or its pharmaceutically acceptable salt dispersed in a solubilizing agent and an erodible material encasing said particles which is capable of forming a hydrogel, can maintain a constant level of cilostazol in the blood through its slow release during its prolonged residence time in the stomach and intestines, thereby minimizing adverse effects caused by rapid release of the drug or solubilizing agent.
摘要翻译：包含分散在增溶剂中的西洛他唑或其药学上可接受的盐和包裹所述能够形成水凝胶的颗粒的易蚀物质的颗粒的控释制剂可以通过其在其血液中缓慢释放而保持恒定水平的西洛他唑在血液中延长了在胃和肠中的停留时间，由此使由药物或增溶剂的快速释放引起的副作用最小化。

9. 发明授权

EP0746311B1 MEDICINAL PATCHES FOR PERCUTANEOUS ADMINISTRATION 失效
标题翻译：医疗石膏percutaneousadministration
公开(公告)号：EP0746311B1
公开(公告)日：2001-07-11
申请号：EP95941909.4
申请日：1995-12-23
申请人： PACIFIC CORPORATION , PACIFIC PHARMACEUTICAL CO. LTD.
发明人： KIM, Jung Ju , BAE, Woo Hyun , LEE, Yoo Chul , CHOI, Yang Gyu, Pacific R & D Center Dormitory
IPC分类号： A61K9/70 , A61K47/10
CPC分类号： A61K9/7053 , A61K9/7061 , A61K9/7092
摘要： Disclosed herein is a transdermal skin patch to adhere to a patient's skin, which comprises a water-impermeable backing layer; a liner; and between the two, a multilayer laminated of from 2 to 5 adhesive layers, each of said adhesive layers comprising an active ingredient, an adhesive resin, and a penetration enhancer, wherein each adhesive layer contains no water and has a different water absorption capacity in which the lowest layer which is to be contacted with the skin has the lowest water absorption capacity and the most upper layer in contact with the backing layer has the highest water absorption capacity, and said penetration enhancer being hexylene glycol present in an amount of 0.5 to 40 % by weight. The patch of the present invention contains hexylene glycol as a penetration enhancer, which allows an efficient enhancement of the penetration of active ingredient through the skin, as well as can be applied to the skin safely.

10. 发明公开

EP1951211A1 TRANSDERMAL PREPARATIONS CONTAINING HYDROPHOBIC NON-STEROIDAL ANTI-INFLAMMATORY DRUGS 有权转让
标题翻译：具有疏水不NSAIDs的透皮制剂
公开(公告)号：EP1951211A1
公开(公告)日：2008-08-06
申请号：EP06799399.8
申请日：2006-10-23
申请人： Amorepacific Corporation , Pacific Pharmaceutical Co., Ltd.
发明人： CHOI, Yang Gyu , AH, Young Chang , CHOI, Woo Jeong , KIM, Jung Ju
IPC分类号： A61K9/70
摘要： Disclosed is a transdermal preparation containing a hydrophobic drug. As a method of continuing the high drug permeation, it is used an unique hydrophilic polymer system in which the drug can be contained in a high concentration under no water environment, a solubility of the hydrophobic drug is decreased as the water is introduced to the patch from the skin, so that the drug is maintained at the saturation concentration even though the drug content is decreased as the drug is permeated to the skin. During the application of the transdermal preparation to the skin, it is possible to continuously permeate the high amount of drug, to maintain the sufficient adhesion during the use and to minimize the skin side effect, because the hydrophilic polymer absorbs the water from the skin. The hydrophilic polymer system can serve the function thereof through the hydrophobic adhesive layer capable of preventing the water quickly absorbed from the skin from being evaporated to the outside of the patch.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式